

CHECKLIST OF RESPONSIBILITIES FOR SCIENTIFIC EDITORS

Manuscript page number: <u>18</u>

Manuscript word count: 3702

		Comments
Item No.	Specific items for verification	Yes=[Y]
		No= [N]
	General Information of the Manuscript	
	Name of journal: World Journal of Clinical Cases	
	Manuscript NO.: 69226	
	Column: Case Report	
	Title: Secondary aortoesophageal fistula initially presented with	
1	empyema after thoracic aortic stent grafting: A case report	[Y]
	Authors: De-Qiong Wang, Mei Liu and Wen-Juan Fan	
	Reviewer code: 05088185	
	First decision: 2021-07-05 01:01	
	Scientific Editor: Kai-Le Chang	
	Date of signature: <u>9/2/2021 (month/day/year)</u>	
	Editorial Office's Comments	
2	Science Editor: The manuscript needs minor revision.	
	Company Editor-in-Chief: I have reviewed the Peer-Review	[Y]
	Report, the full text of the manuscript, the relevant ethics	
	documents, and the English Language Certificate, all of which have	
	met the basic publishing requirements of the World Journal of	
	Clinical Cases, and the manuscript is conditionally accepted. I have	
	sent the manuscript to the author(s) for its revision according to the	



Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors.[Y]3The fixed headings are copied.[Y]The title concisely summarizes the main topic of the study and is not too long (no more than 18 words). Words such as 'exploration', 'research', 'analysis', 'observation', and 'investigation' are avoided. The title does not start with 'The' and does not include any Arabic numbers or uncommon abbreviations.[Y]5A short running title is provided (no more than 6 words).[Y]6names are listed on the title page and are consistent with those listed in the signed BPG Copyright License Agreement form.[Y]The 'Author contributions' passage describes the specific contribution(s) made by each author. The author's names are listed in the following format: full family (sur)name followed by abbreviated first and middles names. e.g., "Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents and[Y]
3The fixed headings are copied.[Y]3The title concisely summarizes the main topic of the study and is not too long (no more than 18 words). Words such as 'exploration', 'research', 'analysis', 'observation', and 'investigation' are avoided.[Y]4'research', 'analysis', 'observation', and 'investigation' are avoided. The title does not start with 'The' and does not include any Arabic numbers or uncommon abbreviations.[Y]5A short running title is provided (no more than 6 words).[Y]6The authors' full family (sur)names and full/abbreviated first names are listed on the title page and are consistent with those listed in the signed BPG Copyright License Agreement form.[Y]7The 'Author contributions' passage describes the specific contribution(s) made by each author. The author's names are listed in the following format: full family (sur)name followed by abbreviated first and middles names. e.g., "Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM performed[Y]
Image: Construction of the study and is not too long (no more than 18 words). Words such as 'exploration', 'research', 'analysis', 'observation', and 'investigation' are avoided.[Y]Image: Construction of the study and is not too long (no more than 18 words). Words such as 'exploration', 'research', 'analysis', 'observation', and 'investigation' are avoided.[Y]Image: Construction of the study and is 'research', 'analysis', 'observation', and 'investigation' are avoided.[Y]Image: Construction of the study and is 'research', 'analysis', 'observation', and 'investigation' are avoided.[Y]Image: Construction of the study and is numbers or uncommon abbreviations.[Y]Image: Construction of the study and is numbers or uncommon abbreviations.[Y]Image: Construction of the study and is names are listed on the title page and are consistent with those listed in the signed BPG Copyright License Agreement form.[Y]Image: Constribution of the study and is abbreviated first and middles names. e.g., "Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed[Y]
4not too long (no more than 18 words). Words such as 'exploration', 'research', 'analysis', 'observation', and 'investigation' are avoided. The title does not start with 'The' and does not include any Arabic numbers or uncommon abbreviations.[Y]5A short running title is provided (no more than 6 words).[Y]6The authors' full family (sur)names and full/abbreviated first names are listed on the title page and are consistent with those listed in the signed BPG Copyright License Agreement form.[Y]7The 'Author contributions' passage describes the specific in the following format: full family (sur)name followed by abbreviated first and middles names. e.g., "Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed[Y]
 4 'research', 'analysis', 'observation', and 'investigation' are avoided. The title does not start with 'The' and does not include any Arabic numbers or uncommon abbreviations. 5 A short running title is provided (no more than 6 words). [Y] The authors' full family (sur)names and full/abbreviated first names are listed on the title page and are consistent with those listed in the signed BPG Copyright License Agreement form. The 'Author contributions' passage describes the specific contribution(s) made by each author. The author's names are listed in the following format: full family (sur)name followed by abbreviated first and middles names. <i>e.g.</i>, "Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM performed
The title does not start with 'The' and does not include any Arabic numbers or uncommon abbreviations.[Y]5A short running title is provided (no more than 6 words).[Y]6The authors' full family (sur)names and full/abbreviated first names are listed on the title page and are consistent with those listed in the signed BPG Copyright License Agreement form.[Y]7The 'Author contributions' passage describes the specific
numbers or uncommon abbreviations.[Y]5A short running title is provided (no more than 6 words).[Y]6The authors' full family (sur)names and full/abbreviated first names are listed on the title page and are consistent with those listed in the signed BPG Copyright License Agreement form.[Y]7The 'Author contributions' passage describes the specific in the following format: full family (sur)name followed by abbreviated first and middles names. e.g., "Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed[Y]
5A short running title is provided (no more than 6 words).[Y]6The authors' full family (sur)names and full/abbreviated first names are listed on the title page and are consistent with those listed in the signed BPG Copyright License Agreement form.[Y]7The 'Author contributions' passage describes the specific contribution(s) made by each author. The author's names are listed in the following format: full family (sur)name followed by abbreviated first and middles names. e.g., "Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed[Y]
6The authors' full family (sur)names and full/abbreviated first names are listed on the title page and are consistent with those listed in the signed BPG Copyright License Agreement form.[Y]The 'Author contributions' passage describes the specific contribution(s) made by each author. The author's names are listed in the following format: full family (sur)name followed by abbreviated first and middles names. e.g., "Wang CL and Liang L contributed equally to this work; Wang[Y]7CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed[Y]
6names are listed on the title page and are consistent with those listed in the signed BPG Copyright License Agreement form.[Y]The 'Author contributions' passage describes the specific contribution(s) made by each author. The author's names are listed in the following format: full family (sur)name followed by abbreviated first and middles names. e.g., "Wang CL and Liang L contributed equally to this work; Wang[Y]7CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed[Y]
Iisted in the signed BPG Copyright License Agreement form.The 'Author contributions' passage describes the specific contribution(s) made by each author. The author's names are listed in the following format: full family (sur)name followed by abbreviated first and middles names. e.g., "Wang CL and Liang L contributed equally to this work; WangCL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed
The 'Author contributions' passage describes the specific contribution(s) made by each author. The author's names are listed in the following format: full family (sur)name followed by abbreviated first and middles names.e.g., "Wang CL and Liang L contributed equally to this work; WangCL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed
 contribution(s) made by each author. The author's names are listed in the following format: full family (sur)name followed by abbreviated first and middles names. e.g., "Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed
 in the following format: full family (sur)name followed by abbreviated first and middles names. <i>e.g.</i>, "Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed
 abbreviated first and middles names. <i>e.g.</i>, "Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed
 <i>e.g.</i>, "Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed
7 CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed [Y]
research study; Wang CL, Zou CC, Hong F and Wu XM performed
the research. Xue IZ and Lu IR contributed new reagents and
the rescalety side j2 and 24 jit contributed new reagents and
analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and
Wang CL, Liang L and Fu JF wrote the manuscript. All authors
have read and approve the final manuscript."
The 'Supported by' statement describes the source(s) of financial
8 support and includes the corresponding identification number(s) [N]
and program ID(s) if available, and contains no spelling errors.
The 'Corresponding author' passage provides the corresponding
9 author's full first and family (sur)names, abbreviated title (<i>e.g.</i> , MD,
PhD), affiliated institute's name and complete postal address
(including zip code) and e-mail (written in all lowercase), and



	contains no spelling errors.	
	The Manuscript Tracking information (<i>i.e.</i> , Received, Peer review	
	started, First decision, Revised, Accepted, Article in press, and	
10	Published online) are provided along with the corresponding editor	[Y]
	and date for each item, and contain no spelling errors.	
	The Abstract section is formatted according to the article-specific	
	style (structured <i>vs</i> unstructured) and word count thresholds, as	
	follows:	
	Commentary, Frontier, Diagnostic Advances, Medical Ethics,	
	Minireview, Review, Therapeutics Advances, and Topic Highlight:	
11	Non-structured abstract that is no less than 200 words.	[Y]
	Field of Vision, Case Report and Letter to the Editor:	
	Non-structured abstract that is no less than 150 words.	
	<u>Research articles:</u> Structured abstract with subsections for AIM (no	
	more than 20 words); METHODS (no less than 80 words); RESULTS	
	(no less than 120 words); and CONCLUSION (no more than 26	
	words).	
	The 'Key words' list provides 5-10 keywords that reflect the main	
12	content of the study. The first letter of each keyword is capitalized,	[Y]
	and each keyword is separated by a semicolon.	
	The "citation" contains authors' names and manuscript title. The	
	name of the first author should be typed in bold letters; the family	
10	(sur) name of all authors should be typed with the first letter	
	capitalized, followed by their abbreviated first and middle initials.	
13	For example, an article by Jae Moon Yoon, Ki Young Son, Chun Sick	[Y]
	Eom, Daniel Durrance, Sang Min Park will be written as Yoon JM,	
	Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes	
	mellitus increases the risk of gastric cancer: A meta-analysis. World J	



	Castrooutoral 2010: In pross	
	<i>Gastroenterol</i> 2019; In press	
14	The 'Core tip' provides a summary (less than 100 words) of the	[Y]
	study that outlines the most innovative and important arguments	
11	and core contents of the paper and will serve to effectively attract	[+]
	readers.	
	The 'INTRODUCTION' section clearly describes the relevant	
	background information for the study. Only the most relevant and	
	current (within the past 5 years) literature is cited, with the	
	exception of rare instances of seminal literature citations. All	
	technical terms and/or abbreviations are explained and/or defined,	
15	with the full name of abbreviations given upon first appearance in	[]]
15	the text and the abbreviation presented in parentheses [i.e.,	[Y]
	"computed tomography (CT)"]. First-person pronouns (e.g., 'I',	
	'we') are used appropriately to clearly indicate the work performed	
	by the author(s). When weaknesses of previous studies are	
	described in the text to highlight the innovations related to the	
	current study, the information is presented carefully.	
	The 'MATERIALS AND METHODS' section clearly and accurately	
16	describes all materials and methods used to obtain the data	[N]
	presented in the article and is adequate for a reader to repeat the	[N]
	study.	
17	The 'RESULTS' section concisely describes the observational and	
	experimental results. Representative data and data that have	[N]
	scientific significance are emphasized. Data is presented in either	
	the text, a table or figure (<i>i.e.</i> , chart, diagram, graph or image), but is	
	not repeated among each. Information presented in the tables and	
	figures clearly describes the trends, meaning, and inferences.	
	Results described in textual form are accurate, concise and clear.	
18	Statistical symbols are accurate. Statistical significance is expressed	[N]
10	as ${}^{a}P < 0.05$, ${}^{b}P < 0.01$ ($P > 0.05$ usually does not need to be denoted).	[1]]



	If there are other series of <i>P</i> values, $^{c}P < 0.05$ and $^{d}P < 0.01$ are used,	
	and a third series of <i>P</i> values is expressed as ${}^{e}P < 0.05$ and ${}^{f}P < 0.01$.	
	Statistical data is expressed as mean \pm SD or mean \pm SE.	
	The 'DISCUSSION' section (1) describes the main purpose and	
	hypothesis of the study; (2) summarizes the most important results;	
	(3) illustrates and explains the results (but does not simply repeat	
19	the data) and draws conclusions or inferences based on the results;	
19	(4) points out the limitations of the study and their impact on the	[Y]
	results, as well as proposes further advice on future research	
	topic(s) or direction(s); and (5) describes the theoretical significance	
	and practical value of the findings.	
	The 'ACKNOWLEDGEMENTS' section expresses gratitude to any	
20	individuals or organizations for technical support (i.e., providing	[N]
	instrumentation, equipment or experimental materials, and/or	
	assistance in experimental work), non-technical services (i.e., useful	
	inspiration, suggestions, guidance, or review), and/or any other	
	auxiliary work.	
01	The 'ARTICLE HIGHLIGHTS' section provides comments for	
21 22	original articles in accordance with the specified format.	[N]
	The 'REFERENCES' section lists the references in the Vancouver	
	style. This style uses Arabic numeral in-text citations based on the	
	order of the first appearance of a source in the text. For citations	[Y]
	where the author's name is indicated in the text, a superscript	
	number should be placed following the name (<i>i.e.,</i> "Pang <i>et al</i> "). For	
	citations where no author is indicated, a superscript number should	
	be placed at the end of the sentence. Respective examples are: "Ma ^[1]	
	reported", "Pan et al ^[2-5] indicated"; "PCR has a high	
	sensitivity ^[6,9] ." No superscript numbers are used when the	
	reference number is described in the text; for example, "The	
	experimental method used has been described in reference [8]." The	
	1	



	style of reference citations in tables is the same as that in the text	
	(e.g., Pan et al ^[2-5] , please see reference [8]).	
	Journal references have been verified to ensure that there are no	
	duplicate references and that the PMID numbers are correct. For	
	references not yet included in PubMed: the name of Chinese	
22	journals is spelled out using Chinese Pinyin, with the first letter of	
23	each word capitalized (e.g., Shijie Huaren Xiaohua Zazhi); the name of	[Y]
	journals in other languages are listed according to indexing	
	information retrieved from Google. Book references are presented	
	with all the information relevant to the electronic version.	
	The number of cited references is appropriate for the article type, as	
	follows:	
24	<u>Commentary:</u> no less than 50;	
24	<u>Review:</u> no less than 100;	[Y]
	<u>Article:</u> no less than 30/26;	
	Case Report and Letter to the Editor: no less than 1.	
	The ethics-related statements are provided in accordance with the	
25	manuscript type (e.g., Manuscript NoInstitutional review board	[N]
	statement, Manuscript NoAnimal care and use statement, etc.).	
	The names of the peer reviewers and the scientific editor are present	
26	at the end of the paper (e.g., P-Reviewer: Hugot D S-Editor: Wang	[Y]
	JL).	



	The order and numerical labeling of tables and figures is consistent	
27	with their appearance and presentation in the text. Symbols in	
	tables (e.g., +, -, \times , \div , *) correctly correspond to the definitions in the	
	footnotes. Only one legend is provided for each multi-panel figure	[1]
	consisting of color graphs, black and white graphs, or line graphs	[Y]
	that depicts data of the same theme. For example: Figure 1	
	Pathological changes in atrophic gastritis tissue before and after	
	treatment. A:; B:; C:; D:; E:; F:	
	Split pictures include flow charts, line graphs, histograms, and	
28	graphs including text. Unsplit pictures include meta-analysis	[Y]
	diagrams, PCR amplification curves, and survival curves.	
29	The author(s) highlighted the changes made to the manuscript	[]]]]
29	according to the peer-reviewers' comments.	[Y]
30	The responses to the peer-reviewers' comments are consistent with	
	the changes made to the manuscript.	[Y]
	The revised manuscript is provided (file name: Manuscript	
31	NoReview; e.g., 870- Review).	
	The letter of peer-reviewers' comments is provided (file name:	[]]
	Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).	[Y]
	The response letter is provided (file name: Manuscript	l
	NoAnswering reviewers; <i>e.g.</i> , 870-Answering reviewers).	
32	The related ethics and relevant documents are provided, such as (1)	
	Approved grant application form(s) or funding agency copy of any	[Y]
	approval document(s) (file name: Manuscript NoGrant application	
	form(s)); (2) Biostatistics review certificate (file name: Manuscript	
	NoBiostatistics statement); (3) Conflict-of-interest statement (file	
	name: Manuscript NoConflict-of-interest statement); (4) Clinical	
	trial registration statement (file name: Manuscript NoClinical trial	
	registration statement); (5) Institutional review board approval form	
	or document (file name: Manuscript NoInstitutional review board	



statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement). All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement). The language certificate provided by authors who are non-native amelage certificate provided by authors who are non-native	
NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement). All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement). The language certificate provided by authors who are non-native	
Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement). All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; <i>e.g.</i> , 870-Copyright license agreement). The language certificate provided by authors who are non-native	
Manuscript NoInformed consent statement). All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement). The language certificate provided by authors who are non-native	
33 All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement). [Y The language certificate provided by authors who are non-native The language certificate provided by authors who are non-native	
33 name: Manuscript NoCopyright license agreement; e.g., 870-Copyright license agreement). [Y The language certificate provided by authors who are non-native [Y	
870-Copyright license agreement). The language certificate provided by authors who are non-native	
The language certificate provided by authors who are non-native]
]
24 measure of English mosts the PDC requirements (file require]
34 speakers of English meets the BPG requirements (file name: [Y	
Manuscript NoLanguage certificate; e.g., 870-Language certificate).	
The photos licensed in the Agreement for Use of Personal Photos	
are consistent with those in the paper (file name: Manuscript	[N]
35 NoAgreement for use of personal photos; e.g., 870-Agreement for	
use of personal photos).	
This document (Checklist of Responsibilities for Scientific Editors)	
36 has been saved under the file name: manuscript NoScientific [Y]
editor work list (e.g., 870-Scientific editor work list).	
A CrossCheck investigation (an effective tool for detecting unoriginal	
content, enabling our editors to preserve the journal's integrity and	
the authors' copyright) has been performed for the manuscript via	
the website: http://www.ithenticate.com/. The results document	
contains the following information for the manuscript: "Name of	[Y]
37 journal", "Manuscript No.", "Columns", "Title" and "Author list".	
The Figure of the <i>CrossCheck</i> results is saved in JPEG format (.jpg) at	
1440 \times 680 pixel resolution. The PDF of the <i>CrossCheck</i> results has	
been saved under the file name: manuscript No CrossCheck report	
(e.g., 870-CrossCheck report). The Google searches have also been	
performed to further ensure publication of original content.	
38 The text of the manuscript is typed in Book Antiqua font, 12 pt, with [Y]



	1.5 line spacing.	
Responsibilities of scientific editors	The primary responsibilities of our scientific editors include carefully entire manuscript and all accompanying materials for: (1) error grammar, punctuation and wording; (2) suitability of tables, figures, fi legends; (3) accurate and appropriate presentation of symbols (<i>e.g.</i> +, tables and figures; and (4) complete and comprehensive revision of t	rs in spelling, igure data and -, ×, ÷, %, *) in
	according to the reviewers' comments.	
Publication process	Manuscript reception and registration \rightarrow Initial review by scientific review \rightarrow End of peer review \rightarrow First round of meeting evalu accepted \rightarrow Revision by the author(s) \rightarrow Second round of meeting evalu accepted/revised/rejected \rightarrow Final review by the Editor-in-Chief control for academic content and language quality) \rightarrow Final acceptance of publication fee \rightarrow Language editing \rightarrow Production \rightarrow Proofreading editor \rightarrow Proofreading by deputy editor \rightarrow Final review by Editor-in-C of online open-access papers in electronic form on the BPG websi online papers on PubMed Central \rightarrow Delivery of high-quality PDF r author(s) \rightarrow End of the publication process.	ation \rightarrow To be uation \rightarrow To be (final quality e and charging by scientific Chief \rightarrow Release te \rightarrow Release of